Health
Prices for Weight-Loss and Diabetes Drugs Like Ozempic Must Drop, UnitedHealth CEO Says
- Witty says US prices are 10 times higher than those in Europe
- He says it’s too early to see any GLP-1 impact on health costs
This article is for subscribers only.
UnitedHealth Group Inc.’s chief executive officer said makers of popular drugs used to control weight and diabetes must cut their prices before employers will widely agree to cover them.
“We’re struggling, and frankly our clients are struggling, with the list prices which have been demanded of these products in the US,” UnitedHealth CEO Andrew Witty said on a call with analysts Friday, noting that US prices are about 10 times higher than those in Western Europe. The treatments generally cost more than $1,000 a month in the US.